Drug maker Lupin on Tuesday announced a 9% rise in net profit at Rs. 291 crore for the quarter ended September 2012, against Rs. 267 crore in the year-ago period, on the back of robust sales across the US, Europe, India and Japan.
During the second quarter, the company’s formulation sales for the US and Europe grew by 40% to Rs. 836 crore against Rs. 598 crore in the corresponding period last fiscal.
The Mumbai-based firm’s India formulations business grew by 18% to Rs. 606 crore during the quarter against Rs. 512 crore in the year-ago period.